Fig. 2
The mechanism of synergistic antitumor effect of oridonin and NVP-BEZ235 on non-GCB DLBCL. a, b Cell lines were treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 24 and 48 h, analyzing apoptosis by Annexin-V/PI staining. c Cell lines were treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 48 h. Western blot analysis was performed to identify the expression of total AKT, p-AKT (Ser473), p-AKT (Thr308), mTOR, and p-mTOR. d Western blot for NF-kB, p-NF-kB, IkBα, and p-IkBα. e The expression of γH2AX and H2AX was analyzed by western blotting. f Cell lines were simultaneously treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) for 48 h, and FACS quantitative analysis of DCF-DA was used to detect the expression of ROS. g Pretreatment of co-treatment group cells with NAC (5 mM) and Z-DEVD-FMK (10 μM), respectively, for 48 h, analyzing apoptosis by Annexin-V/PI staining with t test statistic assay. (Mean ± SD, n = 3, *p < 0.05, **p < 0.01 compared with Ori + BEZ group. Z: Z-DEVD-FMK)